Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 116

1.

Differential enhancement of breast cancer cell motility and metastasis by helical and kinase domain mutations of class IA phosphoinositide 3-kinase.

Pang H, Flinn R, Patsialou A, Wyckoff J, Roussos ET, Wu H, Pozzuto M, Goswami S, Condeelis JS, Bresnick AR, Segall JE, Backer JM.

Cancer Res. 2009 Dec 1;69(23):8868-76. doi: 10.1158/0008-5472.CAN-09-1968. Epub 2009 Nov 10.

2.

Gain of interaction with IRS1 by p110α-helical domain mutants is crucial for their oncogenic functions.

Hao Y, Wang C, Cao B, Hirsch BM, Song J, Markowitz SD, Ewing RM, Sedwick D, Liu L, Zheng W, Wang Z.

Cancer Cell. 2013 May 13;23(5):583-93. doi: 10.1016/j.ccr.2013.03.021. Epub 2013 May 2.

3.

The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells.

Zhao JJ, Liu Z, Wang L, Shin E, Loda MF, Roberts TM.

Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18443-8. Epub 2005 Dec 8.

4.

Signaling via class IA Phosphoinositide 3-kinases (PI3K) in human, breast-derived cell lines.

Juvin V, Malek M, Anderson KE, Dion C, Chessa T, Lecureuil C, Ferguson GJ, Cosulich S, Hawkins PT, Stephens LR.

PLoS One. 2013 Oct 4;8(10):e75045. doi: 10.1371/journal.pone.0075045. eCollection 2013.

5.

Over-expression of the p110beta but not p110alpha isoform of PI 3-kinase inhibits motility in breast cancer cells.

Yip SC, El-Sibai M, Hill KM, Wu H, Fu Z, Condeelis JS, Backer JM.

Cell Motil Cytoskeleton. 2004 Nov;59(3):180-8.

PMID:
15468162
6.

Human tumor mutants in the p110alpha subunit of PI3K.

Liu Z, Roberts TM.

Cell Cycle. 2006 Apr;5(7):675-7. Epub 2006 Apr 1. Review.

PMID:
16627990
7.

Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells.

Isakoff SJ, Engelman JA, Irie HY, Luo J, Brachmann SM, Pearline RV, Cantley LC, Brugge JS.

Cancer Res. 2005 Dec 1;65(23):10992-1000.

9.

Conditional loss of ErbB3 delays mammary gland hyperplasia induced by mutant PIK3CA without affecting mammary tumor latency, gene expression, or signaling.

Young CD, Pfefferle AD, Owens P, Kuba MG, Rexer BN, Balko JM, Sánchez V, Cheng H, Perou CM, Zhao JJ, Cook RS, Arteaga CL.

Cancer Res. 2013 Jul 1;73(13):4075-85. doi: 10.1158/0008-5472.CAN-12-4579. Epub 2013 Apr 30.

10.

Targeting the protein-protein interaction between IRS1 and mutant p110α for cancer therapy.

Hao Y, Zhao S, Wang Z.

Toxicol Pathol. 2014 Jan;42(1):140-7. doi: 10.1177/0192623313506794. Epub 2013 Oct 31. Review.

11.

Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms.

Zhao L, Vogt PK.

Proc Natl Acad Sci U S A. 2008 Feb 19;105(7):2652-7. doi: 10.1073/pnas.0712169105. Epub 2008 Feb 11.

12.

Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit.

Miled N, Yan Y, Hon WC, Perisic O, Zvelebil M, Inbar Y, Schneidman-Duhovny D, Wolfson HJ, Backer JM, Williams RL.

Science. 2007 Jul 13;317(5835):239-42.

13.

A biochemical mechanism for the oncogenic potential of the p110beta catalytic subunit of phosphoinositide 3-kinase.

Dbouk HA, Pang H, Fiser A, Backer JM.

Proc Natl Acad Sci U S A. 2010 Nov 16;107(46):19897-902. doi: 10.1073/pnas.1008739107. Epub 2010 Oct 28.

14.

Regulation of Class IA PI 3-kinases: C2 domain-iSH2 domain contacts inhibit p85/p110alpha and are disrupted in oncogenic p85 mutants.

Wu H, Shekar SC, Flinn RJ, El-Sibai M, Jaiswal BS, Sen KI, Janakiraman V, Seshagiri S, Gerfen GJ, Girvin ME, Backer JM.

Proc Natl Acad Sci U S A. 2009 Dec 1;106(48):20258-63. doi: 10.1073/pnas.0902369106. Epub 2009 Nov 13.

15.

PIK3CA mutation spectrum in urothelial carcinoma reflects cell context-dependent signaling and phenotypic outputs.

Ross RL, Askham JM, Knowles MA.

Oncogene. 2013 Feb 7;32(6):768-76. doi: 10.1038/onc.2012.87. Epub 2012 Mar 19.

PMID:
22430209
16.

Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha.

Sun M, Hillmann P, Hofmann BT, Hart JR, Vogt PK.

Proc Natl Acad Sci U S A. 2010 Aug 31;107(35):15547-52. doi: 10.1073/pnas.1009652107. Epub 2010 Aug 16.

17.

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.

Engelman JA, Chen L, Tan X, Crosby K, Guimaraes AR, Upadhyay R, Maira M, McNamara K, Perera SA, Song Y, Chirieac LR, Kaur R, Lightbown A, Simendinger J, Li T, Padera RF, García-Echeverría C, Weissleder R, Mahmood U, Cantley LC, Wong KK.

Nat Med. 2008 Dec;14(12):1351-6. doi: 10.1038/nm.1890. Epub 2008 Nov 30.

18.

Characterization of a tumor-associated activating mutation of the p110β PI 3-kinase.

Dbouk HA, Khalil BD, Wu H, Shymanets A, Nürnberg B, Backer JM.

PLoS One. 2013 May 29;8(5):e63833. doi: 10.1371/journal.pone.0063833. Print 2013.

19.

Motility enhancement by tumor-derived mutant E-cadherin is sensitive to treatment with epidermal growth factor receptor and phosphatidylinositol 3-kinase inhibitors.

Fuchs M, Hutzler P, Brunner I, Schlegel J, Mages J, Reuning U, Hapke S, Duyster J, Hirohashi S, Genda T, Sakamoto M, Uberall F, Höfler H, Becker KF, Luber B.

Exp Cell Res. 2002 Jun 10;276(2):129-41.

PMID:
12027444
20.

Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.

Jaiswal BS, Janakiraman V, Kljavin NM, Chaudhuri S, Stern HM, Wang W, Kan Z, Dbouk HA, Peters BA, Waring P, Dela Vega T, Kenski DM, Bowman KK, Lorenzo M, Li H, Wu J, Modrusan Z, Stinson J, Eby M, Yue P, Kaminker JS, de Sauvage FJ, Backer JM, Seshagiri S.

Cancer Cell. 2009 Dec 8;16(6):463-74. doi: 10.1016/j.ccr.2009.10.016.

Supplemental Content

Support Center